Substances of Abuse and Their Effect on SAR-CoV-2 Pathogenesis

Overview

Journal NeuroImmune Pharm Ther

Date 2023 Nov 28

PMID 38013836

Authors

Ivy Antwi

Destiny Watkins

Alahn Pedawi

Atheel Ghrayeb

Christine Van de Vuurst

Theodore J Cory

Affiliations

Soon will be listed here.

Abstract

Following the emergence of SARS-CoV-2, various reports suggest that there has been a significant increase in substance abuse due to social distancing and related issues. Several reports have suggested the impact of chronic substance use on individuals' physiological and psychological health. Therefore, there is a need to know the impact of SARS-CoV-2 on persons with substance use disorders. Individuals with substance use disorders are the most vulnerable groups and are at a high risk of SARS-CoV-2 infection due to their already existing health issues associated with substance use. This review discusses some of the molecular and systemic/organic effects chronic substance use such as alcohol, nicotine, marijuana (cannabis), opioids, methamphetamine, and cocaine have on SARS-CoV-2 infectivity and its potential cause for worsened disease outcomes in persons with substance use disorder. This will provide healthcare providers, public health policies, and researchers with the needed knowledge to address some of the many challenges faced during the Covid-19 pandemic to facilitate treatment strategies for persons with substance use disorders.

Citing Articles

COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?.

Michalak A, Lach T, Szczygiel K, Cichoz-Lach H Int J Mol Sci. 2024; 25(4).

PMID: 38396888 PMC: 10888568. DOI: 10.3390/ijms25042212.

References

Mahmud M, Hossain M, Ahmed A, Islam M, Sarker M, Islam M . Antimicrobial and Antiviral (SARS-CoV-2) Potential of Cannabinoids and : A Comprehensive Review. Molecules. 2021; 26(23). PMC: 8658882. DOI: 10.3390/molecules26237216. View

Zhao J, Zhao J, Perlman S . T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010; 84(18):9318-25. PMC: 2937604. DOI: 10.1128/JVI.01049-10. View

Khalsa J, Bunt G, Maggirwar S, Kottilil S . COVID-19 and Cannabidiol (CBD). J Addict Med. 2020; 15(5):355-356. PMC: 8489583. DOI: 10.1097/ADM.0000000000000771. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Wang B, Kovalchuk A, Li D, Rodriguez-Juarez R, Ilnytskyy Y, Kovalchuk I . In search of preventive strategies: novel high-CBD extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging (Albany NY). 2020; 12(22):22425-22444. PMC: 7746344. DOI: 10.18632/aging.202225. View

Farsalinos K, Eliopoulos E, Leonidas D, Papadopoulos G, Tzartos S, Poulas K . Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications. Int J Mol Sci. 2020; 21(16). PMC: 7461543. DOI: 10.3390/ijms21165807. View

Connor J, Stjepanovic D, Le Foll B, Hoch E, Budney A, Hall W . Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021; 7(1):16. PMC: 8655458. DOI: 10.1038/s41572-021-00247-4. View

Szabo G, Saha B . Alcohol's Effect on Host Defense. Alcohol Res. 2015; 37(2):159-70. PMC: 4590613. View

Yasmin F, Najeeb H, Asghar M, Ullah I, Islam S . Increased COVID-19 infection risk, COVID-19 vaccine inaccessibility, and unacceptability: Worrisome trio for patients with substance abuse disorders. J Glob Health. 2021; 11:03106. PMC: 8501395. DOI: 10.7189/jogh.11.03106. View

10.

Perper J, Van Thiel D . Respiratory complications of cocaine abuse. Recent Dev Alcohol. 1992; 10:363-77. DOI: 10.1007/978-1-4899-1648-8_18. View

11.

Byrareddy S, Mohan M . SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?. Brain Behav Immun. 2020; 87:120-121. PMC: 7187842. DOI: 10.1016/j.bbi.2020.04.079. View

12.

Zhou Z, Chen P, Peng H . Are healthy smokers really healthy?. Tob Induc Dis. 2016; 14:35. PMC: 5111288. DOI: 10.1186/s12971-016-0101-z. View

13.

Rossi F, Tortora C, Argenziano M, Di Paola A, Punzo F . Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?. Int J Mol Sci. 2020; 21(11). PMC: 7312493. DOI: 10.3390/ijms21113809. View

14.

Anil S, Shalev N, Vinayaka A, Nadarajan S, Namdar D, Belausov E . Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. Sci Rep. 2021; 11(1):1462. PMC: 7809280. DOI: 10.1038/s41598-021-81049-2. View

15.

Lacagnina M, Rivera P, Bilbo S . Glial and Neuroimmune Mechanisms as Critical Modulators of Drug Use and Abuse. Neuropsychopharmacology. 2016; 42(1):156-177. PMC: 5143481. DOI: 10.1038/npp.2016.121. View

16.

Mrigpuri P, Gupta A, Jha R, Singla P, Singla R . Tobacco use, tuberculosis and Covid-19: A lethal triad. Indian J Tuberc. 2021; 68S:S86-S88. PMC: 8359426. DOI: 10.1016/j.ijtb.2021.08.010. View

17.

Sato K, Sinclair J, Sadeghirad H, Fraser J, Short K, Kulasinghe A . Cardiovascular disease in SARS-CoV-2 infection. Clin Transl Immunology. 2021; 10(9):e1343. PMC: 8423130. DOI: 10.1002/cti2.1343. View

18.

Kandel D . Does marijuana use cause the use of other drugs?. JAMA. 2003; 289(4):482-3. DOI: 10.1001/jama.289.4.482. View

19.

Leung J, Sin D . Smoking, ACE-2 and COVID-19: ongoing controversies. Eur Respir J. 2020; 56(1). PMC: 7363948. DOI: 10.1183/13993003.01759-2020. View

20.

Porubsky S, Kuppe C, Maier T, Birk H, Wornle M, Moeller M . Renal lipidosis in patients enrolled in a methadone substitution program. Arch Pathol Lab Med. 2014; 138(5):689-93. DOI: 10.5858/arpa.2013-0075-CR. View